JPWO2021095779A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021095779A5 JPWO2021095779A5 JP2021556130A JP2021556130A JPWO2021095779A5 JP WO2021095779 A5 JPWO2021095779 A5 JP WO2021095779A5 JP 2021556130 A JP2021556130 A JP 2021556130A JP 2021556130 A JP2021556130 A JP 2021556130A JP WO2021095779 A5 JPWO2021095779 A5 JP WO2021095779A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- lubricant
- orally disintegrating
- disintegrating tablet
- lubricant comprises
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 12
- 239000006191 orally-disintegrating tablet Substances 0.000 claims 12
- 239000004605 External Lubricant Substances 0.000 claims 9
- 239000004610 Internal Lubricant Substances 0.000 claims 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 8
- 239000000314 lubricant Substances 0.000 claims 7
- 229920000881 Modified starch Polymers 0.000 claims 6
- 235000010355 mannitol Nutrition 0.000 claims 6
- 201000000980 schizophrenia Diseases 0.000 claims 6
- 208000028698 Cognitive impairment Diseases 0.000 claims 5
- 208000010877 cognitive disease Diseases 0.000 claims 5
- 239000003826 tablet Substances 0.000 claims 5
- 208000031555 Treatment-Resistant Schizophrenia Diseases 0.000 claims 4
- ZKIAIYBUSXZPLP-UHFFFAOYSA-N brexpiprazole Chemical compound C1=C2NC(=O)C=CC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2 ZKIAIYBUSXZPLP-UHFFFAOYSA-N 0.000 claims 4
- 229960001210 brexpiprazole Drugs 0.000 claims 4
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 4
- 235000019359 magnesium stearate Nutrition 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 4
- 208000024714 major depressive disease Diseases 0.000 claims 3
- 208000020401 Depressive disease Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 208000029252 treatment-refractory schizophrenia Diseases 0.000 claims 2
- 208000017194 Affective disease Diseases 0.000 claims 1
- 208000007415 Anhedonia Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000027691 Conduct disease Diseases 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000036626 Mental retardation Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000027520 Somatoform disease Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 208000012826 adjustment disease Diseases 0.000 claims 1
- 230000001977 ataxic effect Effects 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 208000030963 borderline personality disease Diseases 0.000 claims 1
- 208000026725 cyclothymic disease Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 208000018459 dissociative disease Diseases 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 201000003104 endogenous depression Diseases 0.000 claims 1
- 238000012812 general test Methods 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims 1
- 201000003995 melancholia Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000003152 motion sickness Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 238000005507 spraying Methods 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000010998 test method Methods 0.000 claims 1
- 208000016686 tic disease Diseases 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023201223A JP7676510B2 (ja) | 2019-11-11 | 2023-11-29 | 口腔内崩壊錠 |
| JP2025073996A JP2025118718A (ja) | 2019-11-11 | 2025-04-28 | 口腔内崩壊錠 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPPCT/JP2019/044118 | 2019-11-11 | ||
| PCT/JP2019/044118 WO2021095092A1 (ja) | 2019-11-11 | 2019-11-11 | 口腔内崩壊錠 |
| PCT/JP2020/042114 WO2021095779A1 (ja) | 2019-11-11 | 2020-11-11 | 口腔内崩壊錠 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023201223A Division JP7676510B2 (ja) | 2019-11-11 | 2023-11-29 | 口腔内崩壊錠 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2021095779A1 JPWO2021095779A1 (https=) | 2021-05-20 |
| JPWO2021095779A5 true JPWO2021095779A5 (https=) | 2023-10-16 |
| JP7395607B2 JP7395607B2 (ja) | 2023-12-11 |
Family
ID=75911893
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021556130A Active JP7395607B2 (ja) | 2019-11-11 | 2020-11-11 | 口腔内崩壊錠 |
| JP2023201223A Active JP7676510B2 (ja) | 2019-11-11 | 2023-11-29 | 口腔内崩壊錠 |
| JP2025073996A Pending JP2025118718A (ja) | 2019-11-11 | 2025-04-28 | 口腔内崩壊錠 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023201223A Active JP7676510B2 (ja) | 2019-11-11 | 2023-11-29 | 口腔内崩壊錠 |
| JP2025073996A Pending JP2025118718A (ja) | 2019-11-11 | 2025-04-28 | 口腔内崩壊錠 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220387423A1 (https=) |
| EP (1) | EP4059502A4 (https=) |
| JP (3) | JP7395607B2 (https=) |
| CN (1) | CN114650821A (https=) |
| AU (1) | AU2020384456B2 (https=) |
| CA (1) | CA3161119A1 (https=) |
| PH (1) | PH12022551117A1 (https=) |
| TW (1) | TWI873221B (https=) |
| WO (2) | WO2021095092A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021095092A1 (ja) * | 2019-11-11 | 2021-05-20 | 大塚製薬株式会社 | 口腔内崩壊錠 |
| EP4574134A1 (en) * | 2023-12-22 | 2025-06-25 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A tablet comprising brexpiprazole |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010001106A1 (en) * | 1996-04-16 | 2001-05-10 | Tomohiro Yoshinari | D-mannitol and its preparation |
| JP4358117B2 (ja) * | 2001-03-06 | 2009-11-04 | 協和発酵キリン株式会社 | 口腔内速崩壊錠 |
| US8153161B2 (en) * | 2003-12-09 | 2012-04-10 | Dainippon Sumitomo Pharma Co., Ltd. | Medicament-containing particle and a solid preparation containing the particle |
| JP3996626B2 (ja) * | 2004-06-22 | 2007-10-24 | 塩野義製薬株式会社 | 口腔内速崩壊錠 |
| JP5004236B2 (ja) * | 2005-02-09 | 2012-08-22 | キッセイ薬品工業株式会社 | 口腔内崩壊錠 |
| BRPI0808889A2 (pt) * | 2007-03-13 | 2014-11-11 | Dainippon Sumitomo Pharma Co | Comprimido desintegrante oral |
| US8431618B2 (en) * | 2008-03-31 | 2013-04-30 | Asahi Kasei Chemicals Corporation | Processed starch powder with excellent disintegration properties and manufacturing method thereof |
| CN102119034B (zh) * | 2008-06-13 | 2013-05-22 | 大日本住友制药株式会社 | 在口腔中快速崩解的片剂和制备其的方法 |
| WO2010021300A1 (ja) * | 2008-08-18 | 2010-02-25 | 三菱商事フードテック株式会社 | 新規マンニトール打錠用賦形剤 |
| JP5337430B2 (ja) * | 2008-08-26 | 2013-11-06 | 高田製薬株式会社 | 口腔内速崩壊錠 |
| JP5466880B2 (ja) * | 2009-05-20 | 2014-04-09 | 京都薬品工業株式会社 | 口腔内崩壊錠 |
| JP5733930B2 (ja) * | 2009-09-09 | 2015-06-10 | 武田薬品工業株式会社 | 固形製剤 |
| JO3753B1 (ar) * | 2011-10-14 | 2021-01-31 | Otsuka Pharma Co Ltd | قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه |
| US9827200B2 (en) * | 2012-04-24 | 2017-11-28 | Daiichi Sankyo Company, Limited | Orally disintegrating tablet and production process therefor |
| JP5897196B1 (ja) * | 2015-10-05 | 2016-03-30 | 大同化成工業株式会社 | 糖又は糖アルコール、膨潤型結合剤、崩壊剤及び高吸収性賦形剤を含む複合化造粒物及びその製造方法 |
| CN105412036A (zh) * | 2015-12-24 | 2016-03-23 | 北京康立生医药技术开发有限公司 | 依匹哌唑口腔崩解片 |
| CN106994119A (zh) * | 2016-01-22 | 2017-08-01 | 浙江华海药业股份有限公司 | 含有依匹哌唑或其盐的口腔崩解片及其制备方法 |
| JP6201017B2 (ja) * | 2016-08-04 | 2017-09-20 | 佐藤製薬株式会社 | 硬度及び崩壊性に優れた口腔内崩壊錠の製造方法及び該製造方法により製造される口腔内崩壊錠 |
| WO2021095092A1 (ja) | 2019-11-11 | 2021-05-20 | 大塚製薬株式会社 | 口腔内崩壊錠 |
-
2019
- 2019-11-11 WO PCT/JP2019/044118 patent/WO2021095092A1/ja not_active Ceased
-
2020
- 2020-11-11 TW TW109139356A patent/TWI873221B/zh active
- 2020-11-11 WO PCT/JP2020/042114 patent/WO2021095779A1/ja not_active Ceased
- 2020-11-11 AU AU2020384456A patent/AU2020384456B2/en active Active
- 2020-11-11 PH PH1/2022/551117A patent/PH12022551117A1/en unknown
- 2020-11-11 US US17/755,832 patent/US20220387423A1/en active Pending
- 2020-11-11 CN CN202080078075.5A patent/CN114650821A/zh active Pending
- 2020-11-11 EP EP20887321.6A patent/EP4059502A4/en active Pending
- 2020-11-11 JP JP2021556130A patent/JP7395607B2/ja active Active
- 2020-11-11 CA CA3161119A patent/CA3161119A1/en active Pending
-
2023
- 2023-11-29 JP JP2023201223A patent/JP7676510B2/ja active Active
-
2025
- 2025-04-28 JP JP2025073996A patent/JP2025118718A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107921032B (zh) | 用于治疗神经学疾病或病症的vmat2抑制剂 | |
| Seravalle et al. | Sympathetic nervous system, sleep, and hypertension | |
| TW200418478A (en) | Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | |
| AR059206A1 (es) | Uso de derivados de 4-imidazol para trastornos del snc | |
| JP2015145408A (ja) | 非定型抗精神病薬及びｔａａｒ１アゴニストを含む組合せ | |
| CN118652215A (zh) | Atp合酶反向模式的治疗性调节剂 | |
| AU2022413759A1 (en) | Benzoate salt of 5-methoxy-n,n-dimethyltryptamine | |
| JPWO2021095779A5 (https=) | ||
| Hernandez et al. | Sleep disturbances during shift work | |
| JP2020536045A (ja) | Ａｔｐ合成酵素のリバースモードの治療的阻害剤 | |
| Olivié | Clinical practice: The medical care of children with autism | |
| MX2008000250A (es) | Combinaciones de eszopiclona y trans-4-(3,4-diclorofenil)-1,2,3,4- tetrahidro-n-metil-1-naftalenamina o trans 4-(3,4-diclorofenil)-1, 2,3,4-tetrahidro-1-naftalenamina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y | |
| JP2022180531A5 (https=) | ||
| CN112584831A (zh) | 利鲁唑口腔崩解片用于治疗疾病的用途 | |
| Kamli et al. | Sclareol exerts synergistic antidepressant effects with quercetin and caffeine, possibly suppressing GABAergic transmission in chicks | |
| Ding et al. | Research progress on melatonin, 5-HT, and orexin in sleep disorders of children with autism spectrum disorder | |
| Elvir-Lazo et al. | Impact of chronic medications in the perioperative period: mechanisms of action and adverse drug effects (Part I) | |
| TW200526214A (en) | Treatment of neurological disorders related to rapid eye movement (REM) sleep disturbances with NPY Y5 receptor antagonists | |
| Kokturk et al. | Tryptophan metabolism and sleep | |
| WO2017119456A1 (ja) | せん妄の予防または治療剤 | |
| JP5573677B2 (ja) | ２，３−ジヒドロ−１ｈ−インデン−２−イルウレア誘導体及びその医薬用途 | |
| Yang et al. | Zonisamide: in Parkinson’s disease | |
| Sivagourounadin | Hypnotics and sedatives | |
| JP7167235B2 (ja) | 自閉症スペクトラム障害の予防または治療剤 | |
| TH2201002837A (th) | ยาเม็ดที่แตกตัวในปาก |